Asset divestiture Leverage Aradigm's recent asset liquidation and IP sale to Grifols as a pathway for potential partnerships or acquisition discussions with a focus on respiratory formulations and inhalation delivery assets that may align with your pipeline.

Pulmonary focus Target opportunities in severe respiratory diseases where inhalation-delivered therapies are viable, aligning your portfolio with Aradigm’s specialty in pulmonary drug delivery and leverage their expertise to co-develop or license compatible inhaled treatments.

IP licensing Explore out-licensing or cross-licensing of Aradigm’s respiratory IP and ciprofloxacin formulations to enhance your own inhaled antibiotic or anti-infective programs, especially where resistant respiratory pathogens are a concern.

Strategic partnerships Position a strategic collaboration that complements Aradigm’s capital-conserving strategy by offering late-stage manufacturing, regulatory support, or commercial-scale capabilities in exchange for access to their inhalation technologies.

Revenue and exits Monitor Aradigm’s funding and revenue profile (mid-range annual revenue with prior restructuring and litigation activity) as a bellwether for potential opportunistic investments, asset acquisition, or joint ventures with predictable risk adjusted milestones.